Ocugen, Inc. identified accounting errors in its financial statements and will restate its consolidated financial statements for the year ended December 31, 2022. The errors relate to the company's accounting for costs in a collaboration arrangement and will result in restatements of various financial statement line items. The company also disclosed a material weakness in its internal control over financial reporting. Additionally, the company regained compliance with Nasdaq listing requirements.